AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts [Seeking Alpha]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: Seeking Alpha
FY25 results highlight heavy reliance on milestone-driven revenues, significant cash burn, and a need for tighter cost control to avoid dilution risk. ACI-7104's interim Phase 2 data showed 100% immunogenic responder rate and strong biomarker engagement, with a pivotal final readout expected mid-2026. Valuation reflects cautious optimism; upcoming clinical catalysts and cash runway management will be critical over the next 12–18 months. utah778/iStock via Getty Images Thesis: ACI-7104 to drive upside AC Immune SA ( ACIU reported a FY25 GAAP EPS loss of CHF 0.70. Again, we saw continued losses typical of a clinical-stage biotech company. However, what was concerning was that revenue came This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not rec
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026GlobeNewswire
- Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- AC Immune (ACIU) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
- AC Immune (ACIU) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M [Seeking Alpha]Seeking Alpha
ACIU
Earnings
- 3/13/26 - Miss
ACIU
Sec Filings
- 3/20/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- ACIU's page on the SEC website